SCHEMBL4119220

SCHEMBL4119220

COc1cccc(C(=O)c2cc(Cl)cnc2-n2cccc2)c1OC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.41
NPC1 O15118 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 2/20 0.41
LMNA P02545 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
TUBB4A P04350 4/20 0.39
TUBB P07437 4/20 0.39
TUBA3C P0DPH7 4/20 0.39
TUBA1B P68363 4/20 0.39
TUBA4A P68366 4/20 0.39
TUBB4B P68371 4/20 0.39
TUBB3 Q13509 4/20 0.39
TUBB2A Q13885 4/20 0.39
TUBB8 Q3ZCM7 4/20 0.39
TUBA3E Q6PEY2 4/20 0.39
TUBA1A Q71U36 4/20 0.39
TUBA1C Q9BQE3 4/20 0.39
TUBB6 Q9BUF5 4/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4127808 0.89 ALDH1A1 (0.40) RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E
SCHEMBL4123508 0.82 GAA (0.45) RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E
SCHEMBL4122687 0.80 L3MBTL1 (0.44) RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E
SCHEMBL4116969 0.79 CYP3A4 (0.36) RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E
SCHEMBL4116964 0.79 CYP3A4 (0.36) RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E
SCHEMBL13775255 0.79 CYP3A4 (0.36) RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E
SCHEMBL4110282 0.77 RAB9A (0.41) RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E
SCHEMBL13775248 0.75 ALDH1A1 (0.48) SMN1; SMN2ALDH1A1LMNATUBB4ATUBB
SCHEMBL4117233 0.74 L3MBTL1 (0.41) RAB9ASMN1; SMN2KDM4ELMNANPSR1
SCHEMBL3762150 0.74 RAB9A (0.55) RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
EP-1939205-A1 TRICYCLIC COMPOUND Daiichi Sankyo Company, Limited (JP) 2008-07-02 EP disclosed
EP-1939205-A1 TRICYCLIC COMPOUND Daiichi Sankyo Company, Limited (JP) 2008-07-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181942-A1 TRICYCLIC COMPOUNDS FDFT1, COASY, HMGCR RAB9A 4041/4885NPC1 187/4885SMN1; SMN2 4445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.